Company / Operating Income
Spyre Therapeutics, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$209.6M
FY2025
5-year range
-$242.3M / -$65.6M
FY2021-FY2025
Trend
-0.5%
vs FY2024
Sector context
#146 of 204
Health Care
What the data says
At -$210M, Spyre Therapeutics, Inc.'s operating income ranks #146 of 204 in the Health Care sector. Operating Income has fluctuated over the past 10 years, ranging from -$242M in FY2023 to -$22M in FY2018.
Based on SEC 10-K filings.
-$210M in FY2025.
Improved from -$242M to -$210M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#146 of 204 in Health CareTop 72% of 204This company -$209.6M Sector average $107.7M
▼
-294.5% below sector average
Key checks
Key Insights
- In FY2025, operating income decreased 0.5% year-over-year.
- Ranks #146 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2018.
- Lowest operating income in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$209.6M | -0.5% |
| FY2024 | -$208.6M | +13.9% |
| FY2023 | -$242.3M | -197.4% |
| FY2022 | -$81.5M | -24.1% |
| FY2021 | -$65.6M | -44.4% |
| FY2020 | -$45.5M | -64.3% |
| FY2019 | -$27.7M | -26.3% |
| FY2018 | -$21.9M | +20.8% |
| FY2017 | -$27.7M | -26.3% |
| FY2016 | -$21.9M | -93.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026